View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 6, 2020updated 04 Sep 2020 5:39am

Study finds anti-parasitic drug could kill coronavirus in 48 hours

Researchers from Biomedicine Discovery Institute (BDI) at Monash University in Australia have found that an anti-parasitic drug called Ivermectin could kill the novel coronavirus, SARS-CoV-2, within 48 hours in a laboratory setting.

Researchers from Biomedicine Discovery Institute (BDI) at Monash University in Australia have found that an anti-parasitic drug called Ivermectin could kill the novel coronavirus, SARS-CoV-2, within 48 hours in a laboratory setting.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Monash University, in alliance with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), led the study.

Ivermectin holds the US Food and Drug Administration (FDA) approval as an anti-parasitic medicine. In-vitro, the drug demonstrated activity against different viruses including HIV, dengue, influenza and Zika.

According to findings from the latest study, a single dose of the drug could stop SARS-CoV-2 growing in cell culture within two days.

Monash Biomedicine Discovery Institute scientist Dr Kylie Wagstaff said: “We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it.”

The mechanism of Ivermectin against the coronavirus is still unknown. However, the drug’s action on other viruses indicates that it may block SARS-CoV-2 from diminishing the ability of the host cells to clear it.

Antiviral Research, a journal by Elsevier, published the study findings.

Additional tests and clinical trials in humans must take place to validate the drug’s safety and effectiveness as potential Covid-19 treatment.

In the next research phase, scientists intend to establish the correct dosage for humans to ensure those effective in-vitro are safe.

Dr Wagstaff added: “Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective – that’s the next step.

“In times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world then that might help people sooner. Realistically it’s going to be a while before a vaccine is broadly available.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU